TAS2R3
ENSG00000127362
Target class
GPCR
Chromosome
7
- Chemical probe available
- No
- Other names
- T2R3
- Target name
- TAS2R3
- Gene name
- Taste 2 receptor member 3
- Gene symbol
- TAS2R3
- Protein name
- Taste receptor type 2 member 3 (T2R3)
- Gene biotype
- Protein coding
- Gene family
- Taste 2 receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 0
- Highest tissue expression
- 0.77
- Tissue specificity (Gini)
- 0.458
- Tissue specificity (tau)
- 0.822
- KEGG gene identifiers
- hsa:50831
- Protein interaction confidence
- 0.85175
- Protein interaction partners
- 4
- R-HSA-418594
- R-HSA-420499
- R-HSA-9717207
- End position
- 141765197
- Start position
- 141764097
- Chromosome
- 7
- Strand
- Forward
- Membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.821612
- Expression inequality (Gini)
- 0.458454
Expression in transcripts per million
- Brain - Cerebellum
- 0.77
- Nerve - Tibial
- 0.43
- Ovary
- 0.4
- Brain - Cerebellar Hemisphere
- 0.35
- Skin - Not Sun Exposed (Suprapubic)
- 0.31
Expression in transcripts per million
- Brain - Cerebellum0.77
- Nerve - Tibial0.43
- Ovary0.4
- Brain - Cerebellar Hemisphere0.35
- Skin - Not Sun Exposed (Suprapubic)0.31
- Skin - Sun Exposed (Lower leg)0.3
- Cervix - Ectocervix0.3
- Uterus0.3
- Fallopian Tube0.29
- Cervix - Endocervix0.28
- Vagina0.24
- Cells - EBV-transformed lymphocytes0.23
- Thyroid0.23
- Minor Salivary Gland0.22
- Cells - Cultured fibroblasts0.21
- Small Intestine - Terminal Ileum0.19
- Esophagus - Gastroesophageal Junction0.17
- Bladder0.16
- Breast - Mammary Tissue0.16
- Pituitary0.14
- Testis0.14
- Esophagus - Muscularis0.14
- Colon - Sigmoid0.13
- Adipose - Subcutaneous0.12
- Kidney - Medulla0.11
And 29 more, listed on the interactive page.
Biological processes
- GO:0001580
- GO:0005886
- GO:0016020
- GO:0008527
- GO:0033038
Related records
Trials (132)
- "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"
- A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
- A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
- A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects
- A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine
- A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer
- A Randomized Controlled Trial for Intermittent Preventive Treatment in Pregnancy With Fansidar in Solomon Islands
- A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
- A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh
- A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
- Acceptability and Cost Effectiveness of Home Based Management of Fever: Different Strategies
- ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
- Adjuvant Effect of Chloroquine on Gemcitabine
- An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
- Antimalarial Drug Resistance in Mali
- Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam
- Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia
- Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria
- Assessing a Risk Model for G6PD Deficiency
- Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)